| Rabeprazole |
Pantoprazole will be automatically substituted for other proton
pump inhibitors. When administering PPIs via feeding tubes auto substitute
Lansoprazole Solutabs.
·
Pantoprazole (Protonix), injection and oral,
is the proton pump inhibitor of choice, with automatic substitution for
omeprazole (Prilosecâ), rabeprazole (Aciphexâ),
Lansoprazole (Prevacidâ), and other
oral proton pump inhibitors unless the physician has checked the dispense as
written block.
|
Dosing
Equivalence (mg) |
Lansoprazole
(Prevacid) |
Esomeprazole
(Nexium) |
Omeprazole
(Prilosec) |
Rabeprazole
(Aciphex) |
Pantoprazole
(Protonix) |
|
30 qd |
20 qd |
20 qd |
20 qd |
20 qd |
|
30 qd |
40 qd |
40 qd |
20 qd |
40 qd |
|
30 bid |
20-40 bid |
20-40 bid |
20 bid |
40 bid |
Lanoprazole Solutabs, 15 mg or 30 mg, may be mixed with water
and placed down a very small bore pediatric feeding tube. The granules do not
clump or adhere to the tube.
|
Lanoprazole |
Omeprazole |
|
1-11 years |
<= 30 kg |
15 mg qd |
>= 2 years |
< 20 kg |
10 mg qd |
|
|
> 30 kg |
30 mg qd |
|
>=20 kg |
20 mg qd |
|
12-17 years |
Non erosive GERD |
15 mg qd |
|
|
|
|
|
Erosive GERD |
30 mg qd |
|
|
|
Pantoprazole IV Criteria for use
·
Criteria for use of IV Proton Pump
Inhibitors (PPIs) are list below. If a patient does not meet criteria the
pharmacist will call the physician and/or leave a chart note recommending
conversion to oral therapy.
- Initial treatment of
patients with active upper GI tract bleeding, until they can tolerate oral
therapy, usually after three days of therapy.
- Initial treatment of
patients with Zollinger-Ellison syndrome, until they can tolerate oral therapy
- Stress-ulcer prophylaxis
for critical care patients
- Patients who require PPI
therapy who can not tolerate oral or NG PPI therapy
·
Patients on IV proton pump
inhibitors will have an order entered for the oral route allowing the nurse to
use the oral route when the patient is tolerating oral therapy. Proton pump
inhibitors may be given by the oral route if the patient
does not have active gastrointestinal
bleeding, malabsorption syndrome, short bowel syndrome, severe diarrhea,
uncontrolled nausea and vomiting, continuous nasogastric suctioning, and is not
at risk for aspiration.
|
| Ranitidine |
Autosubstitution with
Famotidine
Famotidine, the P&T preferred H2 antagonist, will be
automatically substituted for ranitidine, cimetidine, nizatidine, other H2
when ordered by the IV or oral route unless the physician has checked the
dispense as written block or the patient is allergic to famotidine.
Dosage Conversion:
Cimetidine Famotidine
300
mg q6-8H 20 mg q12H
300 mg q12-24H 20 mg q24H
400 mg QHS 20 mg QHS
400 mg BID 10 mg BID or 20
mg QHS
400 mg QID 20 mg BID
800 mg QHS 40 mg QHS
800 mg BID 20 mg BID
Ranitidine
50 mg q6-8H IV 20 mg q12H
50 mg
q12-24H IV 20 mg q24H
150 mg QD 20 mg QD
150 mg
BID 20 mg q12h
300 mg QHS
40 mg QHS
Nizatidine
150 mg QD
20 mg QD
150 mg BID
20 mg BID
300 mg QHS
40 mg QHS
|